Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Hainaut

Showing results (151-160 of 164) with videos related to

Pageof 17
Sort By:
Journal of Viral Hepatitis|October 31, 2009
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West AfricaM E Mendy, T Welzel, O A Lesi, et al.
Oncogene|May 10, 2006
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaBV Benoit, E de Moraes, N A Dar, et al.
Cancer Research|September 18, 2001
Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissionsD M DeMarini, S Landi, D Tian, et al.
British Journal of Cancer|June 26, 2008
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinomaA Bengochea, M M de Souza, L Lefrançois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancerM-S Tsao, G Le Teuff, F A Shepherd, et al.
Carcinogenesis|December 4, 2009
TP53 and EGFR mutations in combination with lifestyle risk factors in tumours of the upper aerodigestive tract from South AmericaK Szymańska, J E Levi, A Menezes, et al.
Journal De Pharmacie De Belgique|May 4, 2013
[Rivaroxaban: Xarelto--recommendations for pharmacists]J Douxfils, S Michel, C Beauloye, et al.
Oncogene|June 7, 2011
TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expressionC Ruptier, A De Gaspéris, S Ansieau, et al.
Cancer Letters|February 9, 2010
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern EuropeK Szymańska, L E Moore, N Rothman, et al.
BMJ (Clinical Research Ed.)|February 1, 2005
Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective studyP Vineis, L Airoldi, F Veglia, et al.
Pageof 17

Showing results (151-160 of 164) with videos related to

Sort By:
Pageof 17
Journal of Viral Hepatitis|October 31, 2009
Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West AfricaM E Mendy, T Welzel, O A Lesi, et al.
Oncogene|May 10, 2006
Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaBV Benoit, E de Moraes, N A Dar, et al.
Cancer Research|September 18, 2001
Lung tumor KRAS and TP53 mutations in nonsmokers reflect exposure to PAH-rich coal combustion emissionsD M DeMarini, S Landi, D Tian, et al.
British Journal of Cancer|June 26, 2008
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinomaA Bengochea, M M de Souza, L Lefrançois, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancerM-S Tsao, G Le Teuff, F A Shepherd, et al.
Carcinogenesis|December 4, 2009
TP53 and EGFR mutations in combination with lifestyle risk factors in tumours of the upper aerodigestive tract from South AmericaK Szymańska, J E Levi, A Menezes, et al.
Journal De Pharmacie De Belgique|May 4, 2013
[Rivaroxaban: Xarelto--recommendations for pharmacists]J Douxfils, S Michel, C Beauloye, et al.
Oncogene|June 7, 2011
TP63 P2 promoter functional analysis identifies β-catenin as a key regulator of ΔNp63 expressionC Ruptier, A De Gaspéris, S Ansieau, et al.
Cancer Letters|February 9, 2010
TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern EuropeK Szymańska, L E Moore, N Rothman, et al.
BMJ (Clinical Research Ed.)|February 1, 2005
Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective studyP Vineis, L Airoldi, F Veglia, et al.
Pageof 17